Literature DB >> 2476492

Efficiency and effectiveness of cloned virus-specific cytotoxic T lymphocytes in vivo.

L S Klavinskis1, A Tishon, M B Oldstone.   

Abstract

The efficiency of cloned class I MHC restricted CTL specific for the nucleoprotein or glycoprotein of lymphocytic choriomeningitis virus in either mediating virus clearance or immunopathologic disease in mice during acute infection was quantitated. Cloned CTL specific for either an internal (nucleoprotein) or surface (glycoprotein) protein of lymphocytic choriomeningitis virus, when administered intracerebrally 5 days after the initiation of infection induced fatal immunopathology, indicating that both internal and surface viral Ag play a role in immune mediated disease in vivo. Dose-response analysis indicated that only 10(2) to 10(3) cloned CTL injected intracerebrally were required to induce mortality in 50% of inoculated syngeneic mice. Thus relatively few virus-specific CTL are required to induce an acute immunopathologic disease in the central nervous system. In contrast, if cloned CTL are adoptively transferred at the time of initiation of viral infection they provide protection as demonstrated by their ability to eliminate virus from the brain and thus terminate the acute infection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476492

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  T cells in the central nervous system: the delicate balance between viral clearance and disease.

Authors:  Dorian B McGavern; Dirk Homann; Michael B A Oldstone
Journal:  J Infect Dis       Date:  2002-12-01       Impact factor: 5.226

2.  Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes.

Authors:  L C Dai; K West; R Littaua; K Takahashi; F A Ennis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

3.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  T-cell receptors from virus-specific cytotoxic T lymphocytes recognizing a single immunodominant nine-amino-acid viral epitope show marked diversity.

Authors:  M S Horwitz; Y Yanagi; M B Oldstone
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

5.  Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein.

Authors:  H L Van Epps; C S Schmaljohn; F A Ennis
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Determination of immune cells and expression of major histocompatibility complex class II antigen in encephalitic lesions of experimental Borna disease.

Authors:  U Deschl; L Stitz; S Herzog; K Frese; R Rott
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

8.  Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Authors:  K Kurokohchi; T Akatsuka; C D Pendleton; A Takamizawa; M Nishioka; M Battegay; S M Feinstone; J A Berzofsky
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.

Authors:  R C Hom; R W Finberg; S Mullaney; R M Ruprecht
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Paralysis of street rabies virus-infected mice is dependent on T lymphocytes.

Authors:  M Sugamata; M Miyazawa; S Mori; G J Spangrude; L C Ewalt; D L Lodmell
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.